找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Antiviral Strategies; Hans-Georg Kr?usslich,Ralf Bartenschlager Book 2009 Springer-Verlag Berlin Heidelberg 2009 Antiviral Drug.DNA.Drug R

[復(fù)制鏈接]
樓主: eternal
31#
發(fā)表于 2025-3-26 21:35:28 | 只看該作者
32#
發(fā)表于 2025-3-27 01:28:54 | 只看該作者
33#
發(fā)表于 2025-3-27 05:47:12 | 只看該作者
https://doi.org/10.1007/11545156 infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, although with less success. The antiviral mechanisms of IFNs are reviewed in this chapter as well as the utility of IFNs in the treatment of persistent viral infections.
34#
發(fā)表于 2025-3-27 12:41:50 | 只看該作者
35#
發(fā)表于 2025-3-27 17:15:16 | 只看該作者
36#
發(fā)表于 2025-3-27 18:48:14 | 只看該作者
37#
發(fā)表于 2025-3-27 23:23:43 | 只看該作者
Lecture Notes in Computer Sciencee cycles and, in the context of HIV treatment, contributes to the growing armamentarium of antivirals which, in multidrug combinations, can effectively inhibit viral replication and prevent disease progression.
38#
發(fā)表于 2025-3-28 02:38:13 | 只看該作者
39#
發(fā)表于 2025-3-28 08:59:27 | 只看該作者
Jeremy Rose,Jesper Holgersson,Eva S?derstr?mpidly and will provide further opportunities to explore the efficacy of combination antiviral therapy. While sufficient suppression of HIV RNA and HBV DNA can only be achieved by long-term administration of potent antiviral drugs, HCV RNA may be completely eradicated from the infected individual after a limited duration of treatment.
40#
發(fā)表于 2025-3-28 13:52:13 | 只看該作者
Approaches for the Development of Antiviral Compounds: The Case of Hepatitis C Virus,in Phases 1, 2, and 3, leading to the goal of approved drugs that benefit the infected individual. This review uses hepatitis C virus (HCV), for which we still do not have an ideal therapeutic modality, as an example of the multidisciplinary efforts needed to discover new antiviral drugs for the benefit of humanity.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-24 12:12
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
南陵县| 石首市| 太和县| 项城市| 嘉善县| 大埔区| 志丹县| 和平县| 七台河市| 泰安市| 琼海市| 拉萨市| 嘉黎县| 祁阳县| 望城县| 浦城县| 瓦房店市| 石楼县| 龙川县| 宣化县| 柞水县| 方城县| 弋阳县| 双城市| 陵水| 祁阳县| 东城区| 珠海市| 喀什市| 福建省| 西乡县| 巩留县| 河间市| 肥城市| 镇平县| 峡江县| 清镇市| 揭东县| 株洲县| 黑龙江省| 新民市|